This article was pulled shortly after I commented about it:
"Interesting. Why pick these particular companies from the list of 10,000 that you cite?
I don't know about the other two companies, but in the case of Celsion you are only telling a tiny part of the story, without any mention of their relationship with Hisun, or the VERY POSITIVE post-hoc trial subgroup results, which will be officially released in September at the most prestigious cancer conference in the world.
The P3 trial was poorly conceived by the FDA and Celsion. RF ablation times were not a control (independent) variable, and it needed to be. RFA also needed to be administered closer to an hour after infusion rather than the 15-45 minute window for this trial. There still is a LOT of potential for this delivery mechanism and framework.
Also, I believe your cash-burn rates are inflated by up to 50%. (They have enough cash to last 3-4 years at current burn rates.) And even so, the company has never had a problem raising funds.
So, the prospect for Celsion stock going to zero is just about zero."